ライフサイエンスコーパス: serum cholesterol

1 ea nitrogen, proteinuria, serum albumin, and serum cholesterol).

2 ism is known to be associated with increased serum cholesterol.

3 e at diagnosis, height, body mass index, and serum cholesterol.

4 rse relationship between thyroid hormone and serum cholesterol.

5 similar to those of blood pressure and total serum cholesterol.

6 r cardiovascular disease, including elevated serum cholesterol.

7 ny neurobehavioral effects of low or lowered serum cholesterol.

8 creased LDL receptor expression and elevated serum cholesterol.

9 n agonist to maintain bone density and lower serum cholesterol.

10 which is suppressed by atherogenic levels of serum cholesterol.

11 sity lipoprotein cholesterol (HDL-C) and low serum cholesterol.

12 regulation and achieved stable reductions in serum cholesterol.

13 ccumulation of cholesterol in the liver than serum cholesterol.

14 yceride-lowering activity, T863 also lowered serum cholesterol.

15 henotype, and its inhibition decreases total serum cholesterol.

16 All groups had similar levels of serum cholesterol.

17 , body mass index, plasma ascorbic acid, and serum cholesterol.

18 is was also accompanied by reduced levels of serum cholesterol.

19 eased systemic vascular resistance (by 11%), serum cholesterol (-20%), low-density lipoprotein choles

20 Elevated serum cholesterol accounts for a considerable proportion

21 at BA synthesis contributes to the decreased serum cholesterol after BPD.

22 the statins, drugs widely used for lowering serum cholesterol, also enhance new bone formation in vi

23 There was a nonsignificant increase in total serum cholesterol and a significant increase in serum tr

24 ibrosis, lowered platelet count, and lowered serum cholesterol and alanine aminotransferase (ALT) lev

25 However, studies of the relation between serum cholesterol and all-cause mortality in elderly peo

26 Statins reduce serum cholesterol and cardiovascular morbidity and morta

27 The association between decreased serum cholesterol and colorectal cancer risk suggests a

28 a1(-/-) mice, which were lean and had normal serum cholesterol and glucose levels.

29 acture, or other pathology, body mass index, serum cholesterol and glucose, liver function, blood pre

30 nd IFN therapy are associated with decreased serum cholesterol and high cholesterol has been associat

31 ameters of susceptibility to T2DM, including serum cholesterol and high-density lipoprotein levels.

32 nal risk factors, such as blood pressure and serum cholesterol and homocysteine concentrations, and i

33 ges that included a significant reduction in serum cholesterol and increased fat accumulation in the

34 SIRT1 knockdown also decreased serum cholesterol and increased hepatic free fatty acid

35 This treatment reduced serum cholesterol and inhibited the development of ather

36 Serum cholesterol and insulin resistance were the only i

37 Although serum cholesterol and LDL predictably decreased signific

38 ABCA1-/- mice accompanied by a reduction in serum cholesterol and lipid deposition in various tissue

39 Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels wer

40 he effects of dietary fat and cholesterol on serum cholesterol and on my activities that led to the p

41 that exposure to IH for five days increases serum cholesterol and PL levels, upregulates pathways of

42 We found a direct link between elevated serum cholesterol and reduced insulin secretion, with no

43 hibitors result in substantial reductions in serum cholesterol and stabilization of atherosclerotic p

44 These mice also had reduced serum cholesterol and steatotic livers that was exacerba

45 switch to a control diet for 4 weeks reduced serum cholesterol and stopped lesion growth, and the hig

46 scous, gel-forming fibers, including reduced serum cholesterol and the attenuation of postprandial gl

47 uts and fatty fish in a healthy diet lowered serum cholesterol and triglyceride concentrations, respe

48 d in the liver and exhibited greatly reduced serum cholesterol and triglyceride levels and increased

49 Serum cholesterol and triglyceride levels did not differ

50 Increased serum cholesterol and triglyceride levels were observed,

51 C-III (apoA-I and apoC-III) mRNA levels and serum cholesterol and triglyceride levels, which was not

52 In addition, there was a decrease in serum cholesterol and triglyceride levels.

53 There was a significant decrease in serum cholesterol and triglyceride levels.

54 However, group 1 patients displayed higher serum cholesterol and triglyceride values, as well as lo

55 Lean 3KO mice had significantly lower serum cholesterol and triglycerides as well as improved

56 Constitutive differences in serum cholesterol and triglycerides in PPARalpha-null mi

57 For serum cholesterol and triglycerides, the achievable benc

58 f aortic total cholesterol, as well as lower serum cholesterol and triglycerides, when treated with a

59 mpacts over 14 days including high levels of serum cholesterols and persistent low serum iron level.

60 counseling to produce reductions in weight, serum cholesterol, and (along with antihypertensive medi

61 iNOS-/- mice have a propensity for increased serum cholesterol, and although controversial, several h

62 population, including body mass index (BMI), serum cholesterol, and blood pressure (BP), are also fou

63 ls for such traditional risk factors as BMI, serum cholesterol, and BP should be developed for CHF.

64 n of colorectal cancer risk with statin use, serum cholesterol, and change in cholesterol concentrati

65 Vegans tend to be thinner, have lower serum cholesterol, and lower blood pressure, reducing th

66 se of aspirin after bypass, older age, lower serum cholesterol, and lowest Canadian Functional Class

67 s and had pleiotropic effects on liver mass, serum cholesterol, and serum alanine aminotransferase ac

68 l participants, age, educational attainment, serum cholesterol, and several serum vitamins and carote

69 vascular risk factors, notably hypertension, serum cholesterol, and smoking.

70 Serum, cholesterol, and meconium have been described as

71 ediary markers of risk that are analogous to serum cholesterol are less satisfactory and there are ne

72 Data for trends in serum cholesterol are needed to understand the effects o

73 k factors (heart rate, blood pressure, total serum cholesterol) assessed in 1987 among 693 Italian ma

74 new molecules for the control of cancer and serum cholesterol assisted by tools associated with rati

75 hat the decreased LDL receptor and increased serum cholesterol associated with hypothyroidism are sec

76 Pitavastatin did not reduce total serum cholesterol at any of the doses used.

77 ity, healthy diet, and an optimal profile of serum cholesterol, blood pressure, and glucose; 1 point

78 r age, sex, race, education, serum cotinine, serum cholesterol, body mass index, physical activity, a

79 A (CoA) reductase inhibitors (statins) lower serum cholesterol but exhibit pleiotropic biological eff

80 ease, and a locus on chromosome 9 influenced serum cholesterol but not nephropathy.

81 en developed as food additives to help lower serum cholesterol but there is concern that these additi

82 i-miR-122 TuD but not anti-let-7 TuD reduced serum cholesterol by >30% for 25 weeks in wild-type mice

83 Each episode of rejection increased serum cholesterol by 0.306 mmol/liter (0.258, 0.355) [me

84 of energy, a realistic target, would reduce serum cholesterol by 10% and mortality from ischemic hea

85 ared with placebo, pravastatin lowered total serum cholesterol by 20%, LDL cholesterol by 32%, and tr

86 Atorvastatin lowered total serum cholesterol by about 1.3 mmol/L compared with plac

87 levels approximately 2-fold and lowers total serum cholesterol by up to 36%: this effect is not obser

88 ed accelerated atherosclerosis despite lower serum cholesterol compared with mice reconstituted with

89 unit increase, 1.61; 95% CI, 1.04-2.28), and serum cholesterol concentration (OR per 10-mg/dL [0.25-m

90 mission (HR 0.977 [95% CI 0.957-0.998]), and serum cholesterol concentration at presentation (HR 0.63

91 e association between dietary fat intake and serum cholesterol concentration in adults is unknown.

92 Healthy subjects with a mean (+/-SEM) serum cholesterol concentration of 5.10 +/- 0.18 mmol/L

93 waist-to-hip ratio, systolic blood pressure, serum cholesterol concentration, cigarette smoking, and

94 rated fat and cholesterol raises the average serum cholesterol concentration, leading to a higher ris

95 ently by age, sex, BMI, waist-hip ratio, and serum cholesterol concentration.

96 on all risk factors, rather than simply the serum cholesterol concentration.

97 d pressure, waist and hip circumference, and serum cholesterol concentration; and overnight sleep mon

98 There is some evidence that lower serum cholesterol concentrations (as a surrogate for the

99 bjective was to examine the relation between serum cholesterol concentrations and performance in imme

100 IFN-gamma administration reduced serum cholesterol concentrations by 15% (P = 0.02).

101 Serum cholesterol concentrations have decreased in the U

102 as to quantify the effect of >/=3 g OBG/d on serum cholesterol concentrations in humans and investiga

103 examine the relation between fat intake and serum cholesterol concentrations in men and women whose

104 f high intakes of total and saturated fat on serum cholesterol concentrations in men may be confined

105 turated fat intakes were not associated with serum cholesterol concentrations in men or women.

106 IL-18 administration did not affect serum cholesterol concentrations or lipoprotein-choleste

107 inal assessment of changes in both lipid and serum cholesterol concentrations over 20 years, and comp

108 Lipid and serum cholesterol concentrations were measured in 3572 J

109 , there was no significant difference in the serum cholesterol concentrations, but there were signifi

110 Despite the decrease in serum cholesterol concentrations, IFN-gamma injections s

111 ry bean intake has the potential to decrease serum cholesterol concentrations, improve many aspects o

112 alter arterial blood pressure, body weight, serum cholesterol concentrations, or distribution of lip

113 generally small and inconsistent effects on serum cholesterol concentrations, raising doubts about t

114 for intestinal absorption and thereby lower serum cholesterol concentrations.

115 prandial glucose concentrations and decrease serum cholesterol concentrations.

116 To determine whether higher levels of serum cholesterol could enhance the organ burdens of B.

117 ent risk factor among men with low levels of serum cholesterol, data on 25-year coronary, cardiovascu

118 Total serum cholesterol decreased after PEBD in ALGS patients

119 After 8 months of regression diet (n=9), serum cholesterol decreased to normal, and O2*- levels (

120 The studies on serum cholesterol defined the role of the various classe

121 mg/dL; 95% CI, -2.0 to 14.3 mg/dL; P = .14), serum cholesterol (Delta, -0.6 mg/dL; 95% CI, -5.1 to 4.

122 In contrast, elevated serum cholesterol did not lead to an increase in the spi

123 y was to investigate links between childhood serum cholesterol ester fatty acid (CEFA) proportions an

124 suggest that fat quality as reflected in the serum cholesterol ester fraction in childhood is indepen

125 Serum cholesterol ester is the most suitable serum fract

126 Serum cholesterol ester SFA and PUFA associations were s

127 PUFAs in serum cholesterol esters were measured at baseline in 60

128 Changes in total serum cholesterol followed established dietary correlati

129 Established guidelines for testing of total serum cholesterol for hypercholesterolemia are appropria

130 Estimates of the mean reduction in serum cholesterol from baseline between the OBG and cont

131 se subjects also had fasting blood drawn for serum cholesterol, glucose, and a number of novel biomar

132 e in the prevalence of hypercholesterolemia (serum cholesterol > 200 mg/dL) between the groups.

133 Raised serum cholesterol (>5.0 mmol/L) was found in 48 (44%) pa

134 ter BPD, insulin sensitivity had doubled and serum cholesterol had halved.

135 Statins, used to lower serum cholesterol, have immune-modulating activities.

136 Results were adjusted for age, smoking, serum cholesterol, heavy drinking, adiposity, and, in th

137 Levels of serum cholesterol, high-density lipoprotein cholesterol

138 ions between contemporaneously assayed total serum cholesterol, high-density lipoprotein cholesterol

139 or other risk factors (age, gender, smoking, serum cholesterol, hypertension, diabetes mellitus, and

140 itional CVD risk factors including age, sex, serum cholesterol, hypertension, diabetes, and smoking.

141 The data show that total serum cholesterol in Japanese and Spanish children recen

142 Serum cholesterol in Japanese children was predicted to

143 els of LDL-cholesterol and potently reducing serum cholesterol in mice, and selectively reduce LDL-ch

144 sed hepatic cholesterol content, and lowered serum cholesterol in mice.

145 acceptance of reliable methods for measuring serum cholesterol in nonmedical settings may eventually

146 atherosclerosis in the presence of a similar serum cholesterol in response to a high-fat diet.

147 Ingestion of animal protein raises serum cholesterol in some experimental models but not in

148 Hypercholesterolemia, high serum cholesterol in the form of LDL, is a major risk fa

149 e been extended to children, but the role of serum cholesterol in the neurodevelopment of children is

150 he 3 neurobehavioral tests were unrelated to serum cholesterol in women.

151 and 4.64 (95% CI: 1.93, 7.36) mmol/L higher serum cholesterol in women.

152 Multiple risk factors contribute to elevated serum cholesterol including the use of certain immunosup

153 Serum cholesterol increased from 122+/-7 to 550+/-59 mg/

154 changes were not explained by alterations in serum cholesterol, inflammatory mediators or infiltrates

155 The lowering of serum cholesterol is increasingly recognised as essentia

156 e adaptive immune response and that elevated serum cholesterol is responsible for this effect.

157 Serum cholesterol, LDL levels and triglycerides decrease

158 Plaques were stabilized by reducing serum cholesterol leading to several favorable pathobiol

159 High-fat diet-mediated increases in serum cholesterol, leptin, glucose, and fat accumulation

160 Those with a serum cholesterol level >200 mg/dL had a rate of AVA red

161 all organs examined) mouse models, a reduced serum cholesterol level and an induction of hepatic P450

162 he curvilinear, or log-linear, model between serum cholesterol level and risk for coronary artery dis

163 Recent epidemiologic data show that low serum cholesterol level as well as statin use is associa

164 Significant differences in serum cholesterol level between groups were achieved and

165 CIH caused a greater elevation in serum cholesterol level in ApoE-p50-DKO than in ApoE-KO

166 for middle-aged cohorts (aged 40-64 years), serum cholesterol level is known to be an established ma

167 baseline, 36.7% of patients achieved a total serum cholesterol level less than 5.0 mmol/L, compared w

168 ected 3 cohorts of younger men with baseline serum cholesterol level measurements and no history of d

169 g role, predisposing CHF patients with a low serum cholesterol level to inflammatory consequences of

170 nstrate a continuous, graded relationship of serum cholesterol level to long-term risk of CHD, CVD, a

171 /dL (1.0-mmol/L) increment in baseline total serum cholesterol level was associated with a decreased

172 In contrast, serum cholesterol level was associated with an increased

173 Average serum cholesterol level was lower in the presence of inf

174 ciated with higher risk (P = 0.007), whereas serum cholesterol level was not associated with risk of

175 Serum cholesterol level was significantly (P=0.03) lower

176 nfidence interval, 2.6 to 8.7), and a higher serum cholesterol level were independently related to th

177 Three major coronary risk factors-serum cholesterol level, blood pressure, and smoking-inc

178 es of systolic and diastolic blood pressure, serum cholesterol level, body mass index, presence of di

179 th colorectal cancer, prior cholecystectomy, serum cholesterol level, physical activity, smoking, alc

180 24-hour urinary protein excretion, serum cholesterol level, serum albumin level, creatinine

181 L), and liver for intrahepatic lipids (IHL), serum cholesterol level, serum triglyceride level, and m

182 All major risk factors-age, serum cholesterol level, systolic blood pressure, and ci

183 ng status, history of myocardial infarction, serum cholesterol level, urinalysis proteinuria, urinaly

184 lism, deliver adequate dialysis, and control serum cholesterol level.

185 r body mass index, prior cholecystectomy, or serum cholesterol level.

186 body mass index, diabetes, hypertension, and serum cholesterol level.

187 obese, and 23 patients (27.4%) had elevated serum cholesterol levels (> or =240 mg/dl, 6.22 mmol/L),

188 Men in all 3 cohorts with unfavorable serum cholesterol levels (200-239 mg/dL [5.17-6.18 mmol/

189 wed 4159 subjects with average total and LDL serum cholesterol levels (mean, 209 and 139 mg/dL, respe

190 Whether elevated serum cholesterol levels act as such a factor is unknown

191 Serum cholesterol levels after 32 weeks were 809+/-40 mg

192 n the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in th

193 -dependent LDLR endocytosis promote elevated serum cholesterol levels and can lead to atherosclerosis

194 Because of the strong association between serum cholesterol levels and coronary artery disease, in

195 Serum cholesterol levels and de novo lipid synthesis wer

196 Total serum cholesterol levels and extent and phenotype of ath

197 deletion had no effect on brain and reduced serum cholesterol levels and lovastatin (1.5 mg/kg, twic

198 reductase inhibitor, has been shown to lower serum cholesterol levels and normalize endothelial cell

199 urated nor polyunsaturated fatty acids raise serum cholesterol levels and seemingly pose little risk

200 These mice have significantly different serum cholesterol levels and steady-state brain APOE lev

201 This was related to increased serum cholesterol levels and subsequent hyperlipidemia-i

202 Serum cholesterol levels are some of the most accurate l

203 in cholesterol transport that result in high serum cholesterol levels can affect the pathogenicity of

204 ocardial infarction in patients with average serum cholesterol levels despite the high concurrent use

205 Men with favorable baseline serum cholesterol levels had an estimated greater life e

206 Treatment with simvastatin had no effect on serum cholesterol levels in either normal or hypercholes

207 cal data also suggest cholesterol intake and serum cholesterol levels may be linked with the developm

208 s, and that the pharmacological reduction of serum cholesterol levels may retard prostate cancer grow

209 For men with serum cholesterol levels of 240 mg/dL or greater (>/=6.2

210 The serum cholesterol levels of the ApoE(-) mice were signif

211 ies report an association between cancer and serum cholesterol levels or statin use, while others sug

212 he underlying mechanism of how TFA modulates serum cholesterol levels remains elusive.

213 The serum cholesterol levels rose in all mice fed this diet.

214 n the cuprizone model, acute disease reduces serum cholesterol levels that can be restored by dietary

215 68E-17), which coincides with a tendency for serum cholesterol levels to increase in WD-fed rats (p =

216 As a secondary measure, serum cholesterol levels were assessed.

217 Serum cholesterol levels were determined using a standar

218 Total serum cholesterol levels were elevated similarly in the

219 Nevertheless, no differences in serum cholesterol levels were observed between the H. fe

220 Serum cholesterol levels were unaffected by simvastatin

221 e, estimated glomerular filtration rate, and serum cholesterol levels).

222 d PCSK9 is able to regulate LDL receptor and serum cholesterol levels, although somewhat less efficie

223 and CVD death for younger men with elevated serum cholesterol levels, and longer estimated life expe

224 found concurrent declines in blood pressure, serum cholesterol levels, and the incidence of and morta

225 ed PCSK9 resulted in significantly increased serum cholesterol levels, approaching the increase by in

226 ns preserve endothelial function by reducing serum cholesterol levels, it has been suggested they may

227 Serum cholesterol levels, low-density lipoprotein choles

228 ic plaque remained after accounting for age, serum cholesterol levels, smoking history, and hypertens

229 CYP7A in hamsters results in a reduction of serum cholesterol levels, suggesting that the enzyme pla

230 ses independent of their effects on lowering serum cholesterol levels.

231 amer was found to be effective in decreasing serum cholesterol levels.

232 +antioxidant groups had similar increases in serum cholesterol levels.

233 channels in the kidney, as well as increased serum cholesterol levels.

234 diovascular diseases in populations with low serum cholesterol levels.

235 prevail for men with lower as well as higher serum cholesterol levels.

236 cient mice, despite causing relatively lower serum cholesterol levels.

237 y by drugs in the clinical treatment of high serum cholesterol levels.

238 fe expectancy for younger men with favorable serum cholesterol levels.

239 s and trans fatty acids, both of which raise serum cholesterol levels.

240 ion, bone marrow function, hypertension, and serum cholesterol levels.

241 eraction with SREBP-2 and reduction of liver/serum cholesterol levels.

242 eceptor (LDLR) degradation, thus influencing serum cholesterol levels.

243 on a high fat diet and manifest half-normal serum cholesterol levels.

244 ted fat, total fat, and cholesterol; falling serum cholesterol levels; and a continuing decline in co

245 isoforms can differentially influence total serum cholesterol levels; therefore, APOE has been linke

246 ed toxicities-myelosuppression and increased serum cholesterol/low-density lipoprotein cholesterol-oc

247 e chronic inflammation, in addition to their serum cholesterol-lowering effects, we hypothesized that

248 diet, body mass index <25 kg/m(2), untreated serum cholesterol <200 mg/dL, untreated blood pressure <

249 urrently in two units without the algorithm, serum cholesterol measurements decreased from 5.57 mmol/

250 utamine, tyrosine and isoleucine, along with serum cholesterol measures and atherogenic lipoproteins.

251 ween memory or coding speed and the selected serum cholesterol measures in men, and the scores of the

252 t rest was not significantly correlated with serum cholesterol or insulin resistance (estimated from

253 ined whether there is an association between serum cholesterol or insulin resistance and change in bl

254 s in the BM of recipients but not with total serum cholesterol or percentage of BM-CD31(+)/CD45(low)

255 ma levels of post-heparin LPL activity or in serum cholesterol or triglyceride levels between the 3 g

256 None of the diets altered the serum cholesterol or triglyceride levels in these mice;

257 rmalities but not with higher blood glucose, serum cholesterol, or serum homocysteine levels.

258 protocol to assess surfactant inhibition by serum, cholesterol, or meconium in the captive bubble su

259 ) improves insulin sensitivity and decreases serum cholesterol out of proportion with weight loss.

260 ggulipid did not appear to improve levels of serum cholesterol over the short term in this population

261 .5%; or reoperative CEA, 3.2%) with elevated serum cholesterol (P < 0.017) correlating with early res

262 bservations coincided with reduced levels of serum cholesterol particularly LDL cholesterol observed

263 , p < 0.001), BMI (r = 0.133, p = 0.001) and serum cholesterol (r = 0.094, p = 0.003).

264 pressure during exercise was correlated with serum cholesterol (R>0.47, P<0.0001 for each workload) a

265 mass index, baseline serum glucose, baseline serum cholesterol, recipient age and treated rejection,

266 an exert beneficial effects independently of serum cholesterol reduction by increasing the bioavailab

267 The Pro12Ala polymorphism affected the serum cholesterol response to n-3 PUFA treatment.

268 on, smoking status, systolic blood pressure, serum cholesterol, serum high density lipoprotein choles

269 ed CVD risk factors (high blood pressure and serum cholesterol, smoking, and high blood glucose), hig

270 iovascular risk is inversely correlated with serum cholesterol, suggesting that a process other than

271 l studies revealed that mean levels of total serum cholesterol (TC), low-density lipoproteins (LDLs),

272 ame magnitude as those for men with elevated serum cholesterol, that is, 200-239 and 240 mg/dl.

273 imary mechanism of action is the lowering of serum cholesterol through inhibiting hepatic cholesterol

274 d equation was used to relate differences in serum cholesterol to dietary fat intake.

275 n achieved with this population by mapping a serum cholesterol trait to a 2-Mb region on chromosome 3

276 oe (-/-) mice displayed reduced body weight, serum cholesterol, triglycerides and free fatty acids, s

277 y to the identification of many people whose serum cholesterol, triglycerides, and HDL-cholesterol re

278 on model incorporating age, body mass index, serum cholesterol, triglycerides, HDL cholesterol, insul

279 There was no significant difference in serum cholesterol, triglycerides, low-density lipoprotei

280 rtening, left ventricular ejection fraction, serum cholesterol, uric acid, mixed venous saturation, a

281 sis of dyslipidemia was established when the serum cholesterol value (CHO) was more than 240 mg/dL or

282 ed to improve bone mineral density and lower serum cholesterol values compared with older SERMs in sm

283 or the ratio of pleural fluid cholesterol to serum cholesterol was greater than 0.3 (LR, 14; 95% CI,

284 Increased serum cholesterol was independently associated with decr

285 Serum cholesterol was measured by use of standard method

286 7-0.91); the association was only present if serum cholesterol was measured near the cancer diagnosis

287 Serum cholesterol was similarly elevated in HC and HC+PS

288 Serum cholesterol was unchanged.

289 PCSK9 and LDLR and the resultant effects on serum cholesterol, we produced transgenic mice expressin

290 Diabetes mellitus prevalence and mean serum cholesterol were each associated with greater rela

291 tions of hemoglobin, serum triglyceride, and serum cholesterol were found between the 2 groups.

292 deficient mice that produce large amounts of serum cholesterol were infected with both spirochetes.

293 Previous analyses of trends in serum cholesterol were limited to a few countries, with

294 level higher than 10 mIU/L to elevations in serum cholesterol were rated as fair but data relating t

295 istory, history of diabetes mellitus, and/or serum cholesterol were used to calculate hazard ratios (

296 Obesity-induced changes in serum-cholesterol were blocked in PDE3B(-/-)mice.

297 /-) mice indicated a significant decrease in serum cholesterol when compared with wild-type mice.

298 s shown to be downregulated by elevations in serum cholesterol, which also resulted in invasion of th

299 Attempts at reducing serum cholesterol with different strategies in the past

300 transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side ef